The clinical application of traditional Chinese medicine NRICM101 in hospitalized patients with COVID-19

References

• WHO. Living guidance for clinical management of COVID-19. [cited 2021 January 25]. Available from: https://iris.who.int/bitstream/handle/10665/338882/WHO-2019-nCoV-clinical-2021.1-eng.pdf?fbclid=IwAR12xT-xnppVdLzVz37rnlHAC66kJQ2i6iKfx3o5rhVo0a4dTXgndRMOUt4
   Google Scholar
• Lamontagne F, Agarwal A, Rochwerg B, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020;370:m3379. doi: 10.1136/bmj.m3379
   PubMedGoogle Scholar
• Deng J, Zhou F, Ali S, et al. Efficacy and safety of ivermectin for the treatment of COVID-19: a systematic review and meta-analysis. QJM. 2021;114(10):721–732. doi: 10.1093/qjmed/hcab247
   PubMed Web of Science ®Google Scholar
• Reardon S. Flawed ivermectin preprint highlights challenges of COVID drug studies. Nature. 2021;596(7871):173–174. doi: 10.1038/d41586-021-02081-w
   PubMed Web of Science ®Google Scholar
• Hernandez AV, Ingemi J 3rd, Sherman M, et al. Efficacy of early treatment with hydroxychloroquine in people with mild to moderate COVID-19: a systematic review and meta-analysis. Arch Med Sci. 2022;18(4):939–948. doi: 10.5114/aoms/143147
   PubMed Web of Science ®Google Scholar
• McCabe G, Sahni DS, Ramsaha S. A systematic review on the therapeutic relevance of hydroxychloroquine/chloroquine in the management of COVID-19. Indian J Community Med. 2021;46(3):380–388. doi: 10.4103/ijcm.IJCM_539_20
   PubMed Web of Science ®Google Scholar
• Tanni SE, Bacha HA, Naime A, et al. Use of hydroxychloroquine to prevent SARS-CoV-2 infection and treat mild COVID-19: a systematic review and meta-analysis. J Bras Pneumol. 2021;47(5):e20210236. doi: 10.36416/1806-3756/e20210236
   PubMed Web of Science ®Google Scholar
• Ping YH, Yeh H, Chu LW, et al. The traditional chinese medicine formula jing guan fang for preventing SARS-CoV-2 infection: from clinical observation to basic research. Front Pharmacol. 2022;13:744439. doi: 10.3389/fphar.2022.744439
   PubMed Web of Science ®Google Scholar
• Hu S, Luo D, Zhu Q, et al. An updated meta-analysis of Chinese herbal medicine for the prevention of COVID-19 based on Western-Eastern medicine. Front pharmacol. 2023;14:1257345. doi: 10.3389/fphar.2023.1257345
   PubMedGoogle Scholar
• Bibi S, Khan MS, El-Kafrawy SA, et al. Virtual screening and molecular dynamics simulation analysis of Forsythoside A as a plant-derived inhibitor of SARS-CoV-2 3CLpro. Saudi Pharm J. 2022;30(7):979–1002. doi: 10.1016/j.jsps.2022.05.003
   PubMed Web of Science ®Google Scholar
• Bibi S, Wang YB, Tang DX, et al. Prospects for discovering the secondary metabolites of cordyceps sensu lato by the integrated strategy. Med Chem. 2021;17(2):97–120. doi: 10.2174/1573406416666191227120425
   PubMed Web of Science ®Google Scholar
• Dey D, Hossain R, Biswas P, et al. Amentoflavone derivatives significantly act towards the main protease (3CL(PRO)/M(PRO)) of SARS-CoV-2: in silico admet profiling, molecular docking, molecular dynamics simulation, network pharmacology. Mol Divers. 2023;27(2):857–871. doi: 10.1007/s11030-022-10459-9
   PubMed Web of Science ®Google Scholar
• Li Y, Qin Y, Chen N, et al. Use of traditional Chinese medicine for the treatment and prevention of COVID-19 and rehabilitation of COVID-19 patients: an evidence mapping study. Front Pharmacol. 2023;14:1069879. doi: 10.3389/fphar.2023.1069879
   PubMed Web of Science ®Google Scholar
• Su YC, Huang GJ, Lin JG. Chinese herbal prescriptions for COVID-19 management: special reference to Taiwan Chingguan Yihau (NRICM101). Front Pharmacol. 2022;13:928106. doi: 10.3389/fphar.2022.928106
   PubMed Web of Science ®Google Scholar
• Tsai KC, Huang YC, Liaw CC, et al. A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: a bedside-to-bench study. Biomed Pharmacother. 2021;133:111037. doi: 10.1016/j.biopha.2020.111037
   PubMed Web of Science ®Google Scholar
• Tseng YH, Lin SJ, Hou SM, et al. Curbing COVID-19 progression and mortality with traditional Chinese medicine among hospitalized patients with COVID-19: a propensity score-matched analysis. Pharmacol Res. 2022;184:106412. doi: 10.1016/j.phrs.2022.106412
   PubMed Web of Science ®Google Scholar
• Taiwan Centers for Disease Control. Guideline for clinical management of SARS-CoV-2 infection. Available from: https://www.cdc.gov.tw/Category/Page/xCSwc5oznwcqunujPc-qmQ
   Google Scholar
• Taiwan Society of Pulmonary and Critical Care Medicine. Guideline for clinical management of COVID-19 with acute respiratory failure (v1). [cited 2020 March 17]. Available from: https://www.tspccm.org.tw/media/7453
   Google Scholar
• Taiwan Society of Pulmonary and Critical Care Medicine. Guideline for clinical management of COVID-19 with acute respiratory failure (v2). [cited 2021 May 24]. Available from: https://www.tspccm.org.tw/media/7576
   Google Scholar
• Taiwan Society of Pulmonary and Critical Care Medicine. COVID-19 Taiwan Critical Care Consensus(v1). [cited 2020 April 28]. Available from: https://www.tspccm.org.tw/media/7563
   Google Scholar
• Taiwan Society of Pulmonary and Critical Care Medicine. COVID-19 Taiwan Critical Care Consensus(v2). [cited 2021 May 24]. Available from: https://www.tspccm.org.tw/media/9546
   Google Scholar
• Shang Y, Liu T, Wei Y, et al. Scoring systems for predicting mortality for severe patients with COVID-19. EClinicalMedicine. 2020;24:100426. doi: 10.1016/j.eclinm.2020.100426
   PubMedGoogle Scholar
• Jiang L, An X, Duan Y, et al. The pathological mechanism of the COVID-19 convalescence and its treatment with traditional Chinese medicine. Front Pharmacol. 2022;13:1054312. doi: 10.3389/fphar.2022.1054312
   PubMed Web of Science ®Google Scholar
• Cagino L, Seagly K, Noyes E, et al. Outcomes and management following COVID-19 critical illness. Chest. 2023. doi: 10.1016/j.chest.2023.11.044
   PubMed Web of Science ®Google Scholar
• Tseng YH, Lin SJ, Lee MY, et al. Treating COVID-19 with NRICM101 and NRICM102 - Author’s reply 3. Pharmacol Res. 2022;185:106445. doi: 10.1016/j.phrs.2022.106445
   PubMedGoogle Scholar
• Lin SJ, Lee MY, Tseng YH, et al. Treating COVID-19 with NRICM101 and NRICM102 - Author’s reply. Pharmacol Res. 2022;185:106438. doi: 10.1016/j.phrs.2022.106438
   PubMedGoogle Scholar
• Lee MY, Tseng YH, Lin SJ, et al. Treating COVID-19 with NRICM101 and NRICM102 - Author’s reply 2. Pharmacol Res. 2022;185:106446. doi: 10.1016/j.phrs.2022.106446
   PubMedGoogle Scholar
• Mehendale S, Aung H, Wang CZ, et al. Scutellaria baicalensis and a constituent flavonoid, baicalein, attenuate ritonavir-induced gastrointestinal side-effects. J Pharm Pharmacol. 2007;59(11):1567–1572. doi: 10.1211/jpp.59.11.0015
   PubMed Web of Science ®Google Scholar
• Wang L, Cui X, Cheng L, et al. Adverse events to Houttuynia injection: A systematic review. J Evid Based Med. 2010;3(3):168–176. doi: 10.1111/j.1756-5391.2010.01091.x
   PubMedGoogle Scholar
• Lu YC, Tseng LW, Huang YC, et al. The potential complementary role of using chinese herbal medicine with western medicine in treating COVID-19 patients: pharmacology network analysis. Pharmaceuticals. 2022;15(7):794. doi: 10.3390/ph15070794
   Web of Science ®Google Scholar
• Luo X, Ni X, Lin J, et al. The add-on effect of Chinese herbal medicine on COVID-19: a systematic review and meta-analysis. Phytomedicine. 2021;85:153282. doi: 10.1016/j.phymed.2020.153282
   PubMed Web of Science ®Google Scholar
• Zhang F, Huang J, Liu W, et al. Inhibition of drug-metabolizing enzymes by Qingfei Paidu decoction: Implication of herb-drug interactions in COVID-19 pharmacotherapy. Food Chem Toxicol. 2021;149:111998. doi: 10.1016/j.fct.2021.111998
   PubMed Web of Science ®Google Scholar
• Chang CH, Peng WY, Lee WH, et al. Biotransformation and brain distribution of the anti-COVID-19 drug molnupiravir and herb-drug pharmacokinetic interactions between the herbal extract Scutellaria formula-NRICM101. J Pharm Biomed Anal. 2023;234:115499. doi: 10.1016/j.jpba.2023.115499
   PubMed Web of Science ®Google Scholar